FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Pozen news from FiercePharma

News

GSK rebuked for missing Avandia reports

GlaxoSmithKline got a trip to the FDA woodshed for failing to regularly report post-marketing data it was gathering on the diabetes med Avandia. GSK failed to include updates on as many as 18 Read more...

Press Releases

PRSS RELEASE: Pozen, AstraZeneca Announce Start of the PN 400 Phase III Program

POZEN/AstraZeneca Announce Start of the PN 400 Phase III Program AstraZeneca to Pay an Immediate $30 Million Payment Under Revised Licensing Arrangement CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Read more...

Get more Pozen coverage at: